Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Lexaria Bioscience (LEXX) Operating Margin (2017 - 2026)

Lexaria Bioscience's Operating Margin history spans 10 years, with the latest figure at 7259.52% for Q1 2026.

  • Quarterly results put Operating Margin at 7259.52% for Q1 2026, down 567847.0% from a year ago — trailing twelve months through Feb 2026 was 2571.89% (down 78689.0% YoY), and the annual figure for FY2025 was 1683.01%, down 44385.0%.
  • Operating Margin for Q1 2026 was 7259.52% at Lexaria Bioscience, down from 1545.17% in the prior quarter.
  • In the past five years, Operating Margin ranged from a high of 460.69% in Q1 2024 to a low of 40659.8% in Q3 2022.
  • The 5-year median for Operating Margin is 2290.31% (2022), against an average of 5174.08%.
  • The sharpest move saw Operating Margin tumbled -4063915bps in 2022, then skyrocketed 3703561bps in 2023.
  • Year by year, Operating Margin stood at 1734.71% in 2022, then soared by 57bps to 753.01% in 2023, then tumbled by -94bps to 1462.95% in 2024, then fell by -6bps to 1545.17% in 2025, then plummeted by -370bps to 7259.52% in 2026.
  • According to Business Quant data, Operating Margin over the past three periods came in at 7259.52%, 1545.17%, and 2155.41% for Q1 2026, Q3 2025, and Q2 2025 respectively.